What one share of Elicio Therapeutics holds
We are a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mutant Kirsten rat sarcoma viral oncogene homolog (“mKRAS”) - positive pancreatic cancer, colorectal cancer (“CRC”), lung cancer and other mKRAS positive cancers.
Elicio Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$2.17 |
|---|---|
| Cash and investments | $1.07 |
| Debt | $0.44 |
| Book value | $0.36 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $18.53 | −$515.52 | — | — | — | −$561.00 |
| 2021 | $95.23 | −$183.55 | $1.28 | −$178.35 | — | −$236.35 |
| 2022 | $7.28 | −$89.27 | $2.07 | −$72.26 | — | −$318.92 |
| 2023 | — | −$6.96 | $0.01 | −$6.48 | — | $1.18 |
| 2024 | — | −$4.25 | $0.01 | −$3.04 | — | −$1.03 |
| 2025 | — | −$2.58 | $0.00 | −$2.41 | — | $0.09 |
Common questions about Elicio Therapeutics
How much does one share of Elicio Therapeutics earn?
Over the last 12 months, Elicio Therapeutics lost $2.17 for each share.
Does Elicio Therapeutics pay a dividend?
Elicio Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Elicio Therapeutics’s book value per share?
Elicio Therapeutics’s book value is $0.36 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Elicio Therapeutics have?
Each share of Elicio Therapeutics has $1.07 of cash and investments and $0.44 of debt, as of June 30, 2026.
Has Elicio Therapeutics bought back shares?
Elicio Therapeutics’s share count rose about 9754% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.